Lifecore Biomedical Shareholders Seek Reforms After Securities Fraud Settlement

Grabar Law Office investigates claims on behalf of long-term Lifecore shareholders following class action settlement.

Jan. 30, 2026 at 9:55am

Got story updates? Submit your updates here. ›

Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) after a securities fraud class action against the company reached a $3.75 million settlement. The investigation concerns whether certain Lifecore officers and directors breached their fiduciary duties to the company. Current Lifecore shareholders who have held shares since before October 7, 2020 can seek corporate reforms, the return of funds to the company, and a court-approved incentive award at no cost.

Why it matters

The settlement of this securities fraud class action highlights concerns about Lifecore's internal financial controls and the accuracy of its public disclosures. Long-term shareholders are now seeking to hold the company and its leadership accountable through corporate reforms and the return of funds.

The details

The underlying class action complaint alleges that Lifecore made materially false and misleading statements about its business, operations, and prospects. Specifically, the complaint claims Lifecore had deficient internal financial controls, issued inaccurate financial statements that required restatement, and failed to timely file periodic reports with the SEC, all of which impaired the company's financial position and prospects.

  • The class action was filed against Lifecore Biomedical, Inc. (NASDAQ: LFCR) and certain of its officers.
  • Lifecore and individual defendants have entered into an agreement in principle with the plaintiffs to settle the class action for $3,750,000.

The players

Lifecore Biomedical, Inc.

A NASDAQ-listed company that provides contract development and manufacturing services for the pharmaceutical and medical device industries.

Grabar Law Office

A nationally recognized law firm with extensive experience in complex commercial litigation, including securities class actions and shareholder litigation.

Joshua Grabar

The founder of Grabar Law Office, who is leading the investigation on behalf of Lifecore shareholders.

Got photos? Submit your photos here. ›

What they’re saying

“Current Lifecore Biomedical, Inc. (NASDAQ: LFCR) who have held shares since before October 7, 2020, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.”

— Joshua Grabar, Founder, Grabar Law Office (Grabar Law Office)

What’s next

The judge in the case will decide on whether to approve the $3.75 million settlement between Lifecore and the plaintiffs.

The takeaway

This settlement underscores the importance of strong internal controls and accurate financial reporting for publicly traded companies. Long-term Lifecore shareholders are now seeking to hold the company accountable and implement reforms to protect their investments.